Jorge E. (Cortes) Cortes-Franco MD (He/Him)

PubMed

• Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results.
  Jorge E Cortes, Fabian Lang, Delphine Rea, Andreas Hochhaus, Massimo Breccia
  Leukemia. 2025-04-09
• Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1treated with at least 2 prior TKIs: Phase 1 final results.
  Andreas Hochhaus, Dong-Wook Kim, Jorge E Cortes, Koji Sasaki, Michael J Mauro
  Leukemia. 2025-04-09
• Asciminib: the tyrosine kinase inhibitor with a unique mechanism of action.
  Akriti G Jain, Jorge E Cortes
  Expert Opinion on Pharmacotherapy. 2025-04-01

Lectures

• Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial. 
  2019 ASCO Annual Meeting - 6/1/2019
• Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Pregnancy Outcomes in Patients Treated with Bosutinib 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of Cytogenetic Stratifications in Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Population Pharmacokinetic/Pharmacodynamic Evaluation of the Relationship between Glasdegib Treatment/ Exposure and Overall Survival in AML Patients 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older P... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enr... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia – Final Results of a Prospective Phase 2 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leu... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)Clinicall... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase 3, randomized, placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Join now to see all